Efficacy of Oral Medication in Weight Loss Management: A Systematic Review and Network Meta-Analysis.

Benedictus B, Pratama VK, Purnomo CW, Tan K, Febrinasari RP

Clinical therapeutics21 Jan 2025Cited by 5 (Europe PMC)

PMID39843265DOI10.1016/j.clinthera.2024.12.013PepBankPUB-39843265

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. 1 result from people.

01HumanSystematic reviewEfficacy outcome
In adults with obesity, network meta-analysis estimated a mean weight difference of -2.92 for semaglutide, with a 95% CI of -4.38 to -1.46.
In plain wordsIn adults with obesity, a pooled analysis found that semaglutide led to weight loss.
Peptide
Semaglutide
Outcome
DecreaseWeight loss, network meta-analysis estimate
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Mean difference
−2.92 NA
semaglutide
Source sentences
Summary
semaglutide (MD, -2.92; 95% CI, -4.38 to -1.46)
2 context sentences(design, population, supporting numbers)
Summary · context
This systematic review was conducted to determine which type of oral medication for obesity provides the best weight loss effect.
Summary · context
Eighteen randomized controlled trials, with a total population of 12,259 patients, were included.
Report a problemFND-3984326501

Studies that did not test the peptide alone2

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

02HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In the network meta-analysis of oral obesity drugs, there were no significant differences among the drug groups.
In plain wordsIn the pooled analysis, no oral obesity drug was clearly better than the others for weight loss.
Peptide
Semaglutide
Outcome
No significant changeWeight loss differences among oral obesity drugs
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
There were no significant differences among the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This systematic review was conducted to determine which type of oral medication for obesity provides the best weight loss effect.
Summary · context
Eighteen randomized controlled trials, with a total population of 12,259 patients, were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3984326502
03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In adults with obesity, all oral obesity drugs pooled gave greater weight loss than placebo (mean difference -2.12).
In plain wordsIn adults with obesity, oral obesity drugs as a group led to more weight loss than placebo.
Peptide
Semaglutide
Outcome
DecreaseWeight loss with all oral obesity drugs versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Mean difference
−2.12 NA
all oral obesity therapies
Source sentences
Summary
However, compared with placebo, all oral obesity therapies provide better benefits in weight loss (MD, -2.12; 95% CI, -2.64 to -1.59; P ≤ 0.00001).
2 context sentences(design, population, supporting numbers)
Summary · context
This systematic review was conducted to determine which type of oral medication for obesity provides the best weight loss effect.
Summary · context
Eighteen randomized controlled trials, with a total population of 12,259 patients, were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3984326503

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.